KR20040072697A - 피롤리돈 카르복사미드 - Google Patents

피롤리돈 카르복사미드 Download PDF

Info

Publication number
KR20040072697A
KR20040072697A KR10-2004-7010431A KR20047010431A KR20040072697A KR 20040072697 A KR20040072697 A KR 20040072697A KR 20047010431 A KR20047010431 A KR 20047010431A KR 20040072697 A KR20040072697 A KR 20040072697A
Authority
KR
South Korea
Prior art keywords
rac
carboxamide
phenyl
oxopyrrolidine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2004-7010431A
Other languages
English (en)
Korean (ko)
Inventor
이슬러마르쿠스
길러토마스
슈발름귄터
슈테거마티아스
힐페르트쿠르트
발덴아이레올리버
브로이폴커
Original Assignee
액테리온 파마슈티칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액테리온 파마슈티칼 리미티드 filed Critical 액테리온 파마슈티칼 리미티드
Publication of KR20040072697A publication Critical patent/KR20040072697A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR10-2004-7010431A 2001-12-31 2002-12-27 피롤리돈 카르복사미드 Withdrawn KR20040072697A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH23812001 2001-12-31
CH2381/01 2001-12-31
CH0200429 2002-08-05
CHPCT/CH02/00429 2002-08-05
PCT/CH2002/000725 WO2003059905A1 (de) 2001-12-31 2002-12-27 Pyrrolidon-carboxamide

Publications (1)

Publication Number Publication Date
KR20040072697A true KR20040072697A (ko) 2004-08-18

Family

ID=25705687

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7010431A Withdrawn KR20040072697A (ko) 2001-12-31 2002-12-27 피롤리돈 카르복사미드

Country Status (8)

Country Link
EP (1) EP1463724A1 (https=)
JP (1) JP2005521651A (https=)
KR (1) KR20040072697A (https=)
CN (1) CN100534990C (https=)
AU (1) AU2002350366A1 (https=)
CA (1) CA2471620A1 (https=)
MX (1) MXPA04006458A (https=)
WO (1) WO2003059905A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
JP4726243B2 (ja) * 2005-08-09 2011-07-20 第一三共株式会社 新規セルコスポラミド誘導体
WO2007018193A1 (ja) * 2005-08-09 2007-02-15 Daiichi Sankyo Company, Limited 新規セルコスポラミド誘導体
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2480531B1 (en) * 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
CN102827056B (zh) * 2012-09-03 2014-07-23 华东理工大学 N-芳基取代吡咯烷酮衍生物及其用途
EP3126346B1 (en) * 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US10968176B2 (en) 2014-09-14 2021-04-06 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers
EP3194365A4 (en) * 2014-09-14 2018-04-25 Nanosynthons LLC Pyrrolidone derivatives, oligomers and polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB856452A (en) * 1957-06-27 1960-12-14 Bayer Ag Protective agents against textile pests, mould and bacteria
US5281612A (en) * 1982-09-09 1994-01-25 Warner-Lambert Company Naphthyridine antibacterial agents
DE69025418T2 (de) * 1989-04-19 1996-11-14 Otsuka Pharma Co Ltd Phenylcarbonsäurederivate mit einem Heterocyclus
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
AU6000900A (en) * 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
GB0010757D0 (en) * 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
JP2005521651A (ja) 2005-07-21
WO2003059905A1 (de) 2003-07-24
EP1463724A1 (de) 2004-10-06
CN100534990C (zh) 2009-09-02
CN1610678A (zh) 2005-04-27
AU2002350366A1 (en) 2003-07-30
MXPA04006458A (es) 2004-10-04
CA2471620A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
KR20040072697A (ko) 피롤리돈 카르복사미드
JP3108719B2 (ja) 新規なｎ−アルキレンピペリジノ化合物及びそのエナンチオマー；これらを合成する方法及びこれらを含む医薬品組成物
EP1257539B1 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
EP0591040B1 (fr) Amides basiques quaternaires comme antagonistes des tachykinines
AU662960B2 (en) N-sulphonyl-2-oxoindole derivatives having affinity for vasopressin and/or ocytocin receptors
EP0512901B1 (fr) Composés polycycliques aminés et leurs énantiomères, procédé pour leur préparation et compositions pharmaceutiques en contenant
EP0474561B1 (fr) Arylalkylamines, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP1680418B1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
AU2008206759B2 (en) Nicotinic acetylcholine receptor modulators
JPH05262732A (ja) 新規ｎ−ジアルキレンピペリジノ化合物及びそのエナンチオマー、その製造方法、及びそれを含む薬学的組成物
JPH08508738A (ja) ５−ｈｔ１ａ及び／又は５−ｈｔ２リガンドとしてのインドール誘導体
EP0576357A1 (fr) Dérivés du pyrazole, procédé pour leur préparation et compositions pharmaceutiques les contenant
JP2007510702A (ja) 代謝性疾患の処置に有用な１１−β−ＨＳＤ１阻害剤としてのＮ−アシル化−３−（ベンゾイル）−ピロリジン
KR20010081112A (ko) 벤즈아미드 유도체들 및 그들의 ａｐｏｂ-100 분비억제제로서의 용도
CA2555216C (fr) Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2021514963A (ja) ニューロトロフィンに関連する疾患を治療するためのトリアジン誘導体
JP2007523147A (ja) 肥満の処置のためのピロール−３−カルボキサミド誘導体
EP0694536A1 (fr) Dérivés de 1-benzyl-1,3-dihydro-2H-benzimidazol-2-one, leur préparation, et compositions pharmaceutiques les contenant
KR20000005505A (ko) 피페리딘 및 피롤리딘
US20040024215A1 (en) Benzamide derivatives and their use as apob-100 and mtp inhibitors
US7317025B2 (en) Non-peptidic NPY Y2 receptor inhibitors
CA2175498C (en) Phenylindole compounds
US7067549B2 (en) Pyrrolidone carboxamides
EP2108012A2 (fr) Derives de n-(4-cyano-l h-p yrazol-3 -yl)methylamine substitues, leur preparation et leur application en therapeutique
JP2008546829A (ja) ４，５−ジアリールピロール誘導体、この調製方法および治療におけるこの使用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040630

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid